Therapeutic strategies with oral fluoropyrimidine anticancer agent, S-1 against oral cancer
Oral cancer has been recognized as a tumor with low sensitivity to anticancer agents. However, introduction of S-1, an oral cancer agent is improving treatment outcome for patients with oral cancer. In addition, S-1, as a main drug for oral cancer treatment in Japan can be easily available for outpa...
Main Authors: | Koji Harada, Tarannum Ferdous, Yoshiya Ueyama |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2017-08-01
|
Series: | Japanese Dental Science Review |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1882761616300618 |
Similar Items
-
Survival and toxicity outcomes of induction chemotherapy followed by concurrent chemoradiotherapy compared with concurrent chemoradiotherapy alone in inoperable stage III and IVA/B head and neck cancer
by: Sajib Kumar Talukdhar, et al.
Published: (2022-03-01) -
Preventive Effect of Rebamipide Gargle on Chemoradiotherpy-Induced Oral Mucositis in Patients with Oral Cancer: a Pilot Study
by: Takashi Yasuda, et al.
Published: (2011-11-01) -
Adjuvant Chemo-Radiotherapy versus Chemotherapy in Pancreatic Carcinoma
by: Shimaa Attia, et al.
Published: (2017-06-01) -
The prevalence of chemotherapy side effects of cancerous patients on oral health
by: EshghyarN, et al.
Published: (2001-09-01) -
Oral-Gut Microbiome Axis in the Pathogenesis of Cancer Treatment-Induced Oral Mucositis
by: Ghanyah Al-Qadami, et al.
Published: (2022-03-01)